Utilizing a novel technology called Particle Replication In Non-Wetting Templates (PRINT) platform, Liquidia is developing rationally designed carriers for improved delivery of small molecule and biological cargos.
Liquidia Technologies CEO Neal Fowler said by improving vaccine performance and reducing manufacturing costs using its PRINT technology, they hope this collaboration has the potential to impact the spread of pneumonia in the developing world.
Path Pneumococcal vaccine project director Mark Alderson said technologies such as PRINT may help them find safe and effective pneumococcal vaccines that can be delivered to a global population in a cost-effective manner.
"Path is committed to working with scientists and manufacturers to advance vaccines that can prevent the spread of pneumonia and other pneumococcal diseases among children in the developing world," Alderson added.